Terje Sundstrøm1, Heidi Espedal1, Patrick N Harter1, Kristine Eldevik Fasmer1, Kai Ove Skaftnesmo1, Sindre Horn1, Erlend Hodneland1, Michel Mittelbronn1, Benjamin Weide1, Rudi Beschorner1, Benjamin Bender1, Cecilie Brekke Rygh1, Morten Lund-Johansen1, Rolf Bjerkvig1, Frits Thorsen1. 1. Department of Biomedicine, University of Bergen, Bergen, Norway (T.S., H.E., K.O.S., S.H., E.H., C.B.R., R.Bj., F.T.); Department of Clinical Medicine, University of Bergen, Bergen, Norway (T.S., M.L.-J.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (T.S., M.L.-J.); Edinger-Institute (Neurological Institute), Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H., M.M.); Center for Nuclear Medicine/PET, Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway (K.E.F.); Department of Dermatology, University Medical Center, Tübingen, Germany (B.W.); Department of Immunology, University of Tübingen, Tübingen, Germany (B.W.); Department of Neuropathology, Institute for Pathology and Neuropathology, University of Tübingen, Tübingen, Germany (R.Be.); Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany (B.B.); NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (R.Bj.).
Abstract
BACKGROUND: The key metabolic enzyme lactate dehydrogenase A (LDHA) is overexpressed in many cancers, and several preclinical studies have shown encouraging results of targeted inhibition. However, the mechanistic importance of LDHA in melanoma is largely unknown and hitherto unexplored in brain metastasis. METHODS: We investigated the spatial, temporal, and functional features of LDHA expression in melanoma brain metastasis across multiple in vitro assays, in a robust and predictive animal model employing MRI and PET imaging, and in a unique cohort of 80 operated patients. We further assessed the genomic and proteomic landscapes of LDHA in different cancers, particularly melanomas. RESULTS: LDHA expression was especially strong in early and small brain metastases in vivo and related to intratumoral hypoxia in late and large brain metastases in vivo and in patients. However, LDHA expression in human brain metastases was not associated with the number of tumors, BRAF(V600E) status, or survival. Moreover, LDHA depletion by small hairpin RNA interference did not affect cell proliferation or 3D tumorsphere growth in vitro or brain metastasis formation or survival in vivo. Integrated analyses of the genomic and proteomic landscapes of LDHA indicated that LDHA is present but not imperative for tumor progression within the CNS, or predictive of survival in melanoma patients. CONCLUSIONS: In a large patient cohort and in a robust animal model, we show that although LDHA expression varies biphasically during melanoma brain metastasis formation, tumor progression and survival seem to be functionally independent of LDHA.
BACKGROUND: The key metabolic enzyme lactate dehydrogenase A (LDHA) is overexpressed in many cancers, and several preclinical studies have shown encouraging results of targeted inhibition. However, the mechanistic importance of LDHA in melanoma is largely unknown and hitherto unexplored in brain metastasis. METHODS: We investigated the spatial, temporal, and functional features of LDHA expression in melanoma brain metastasis across multiple in vitro assays, in a robust and predictive animal model employing MRI and PET imaging, and in a unique cohort of 80 operated patients. We further assessed the genomic and proteomic landscapes of LDHA in different cancers, particularly melanomas. RESULTS:LDHA expression was especially strong in early and small brain metastases in vivo and related to intratumoral hypoxia in late and large brain metastases in vivo and in patients. However, LDHA expression in humanbrain metastases was not associated with the number of tumors, BRAF(V600E) status, or survival. Moreover, LDHA depletion by small hairpin RNA interference did not affect cell proliferation or 3D tumorsphere growth in vitro or brain metastasis formation or survival in vivo. Integrated analyses of the genomic and proteomic landscapes of LDHA indicated that LDHA is present but not imperative for tumor progression within the CNS, or predictive of survival in melanomapatients. CONCLUSIONS: In a large patient cohort and in a robust animal model, we show that although LDHA expression varies biphasically during melanoma brain metastasis formation, tumor progression and survival seem to be functionally independent of LDHA.
Authors: Han Xie; Jun-Ichi Hanai; Jian-Guo Ren; Lev Kats; Kerri Burgess; Parul Bhargava; Sabina Signoretti; Julia Billiard; Kevin J Duffy; Aaron Grant; Xiaoen Wang; Pawel K Lorkiewicz; Sabrina Schatzman; Michael Bousamra; Andrew N Lane; Richard M Higashi; Teresa W M Fan; Pier Paolo Pandolfi; Vikas P Sukhatme; Pankaj Seth Journal: Cell Metab Date: 2014-04-10 Impact factor: 27.287
Authors: Benjamin Weide; Sabina Richter; Petra Büttner; Ulrike Leiter; Andrea Forschner; Jürgen Bauer; Laura Held; Thomas Kurt Eigentler; Friedegund Meier; Claus Garbe Journal: PLoS One Date: 2013-11-28 Impact factor: 3.240
Authors: Michael Krauthammer; Yong Kong; Byung Hak Ha; Perry Evans; Antonella Bacchiocchi; James P McCusker; Elaine Cheng; Matthew J Davis; Gerald Goh; Murim Choi; Stephan Ariyan; Deepak Narayan; Ken Dutton-Regester; Ana Capatana; Edna C Holman; Marcus Bosenberg; Mario Sznol; Harriet M Kluger; Douglas E Brash; David F Stern; Miguel A Materin; Roger S Lo; Shrikant Mane; Shuangge Ma; Kenneth K Kidd; Nicholas K Hayward; Richard P Lifton; Joseph Schlessinger; Titus J Boggon; Ruth Halaban Journal: Nat Genet Date: 2012-07-29 Impact factor: 38.330
Authors: Terje Sundstrøm; Lars Prestegarden; Francisco Azuaje; Synnøve Nymark Aasen; Gro Vatne Røsland; Jobin K Varughese; Marzieh Bahador; Simon Bernatz; Yannick Braun; Patrick N Harter; Kai Ove Skaftnesmo; Elizabeth S Ingham; Lisa M Mahakian; Sarah Tam; Clifford G Tepper; Kjell Petersen; Katherine W Ferrara; Karl Johan Tronstad; Morten Lund-Johansen; Rudi Beschorner; Rolf Bjerkvig; Frits Thorsen Journal: Acta Neuropathol Commun Date: 2019-04-10 Impact factor: 7.801